Photodynamic Therapy for Glioblastoma Multiforme Based on Metaverse and Yellow Fluorescence
Study on Precision Photodynamic Therapy for Glioblastoma Multiforme Based on Metaverse and Yellow Fluorescence
1 other identifier
observational
100
1 country
1
Brief Summary
GBM patients receiving PDT treatment (50 cases，surgery combined with photodynamic therapy) and traditional treatment (50 cases，traditional surgery) in our hospital and partner hospitals were collected. The prognosis was analyzed by comparing with the control group from multiple perspectives such as image evaluation, imaging effect, Karnofsky score, median survival time and survival rate.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jun 2025
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 10, 2025
CompletedFirst Posted
Study publicly available on registry
April 22, 2025
CompletedStudy Start
First participant enrolled
June 1, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2027
April 22, 2025
January 1, 2025
2.1 years
February 10, 2025
April 14, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Number of Participants with Treatment of Surgical combination Photodyanmic therapy
From June 2025 to June 2027
Study Arms (2)
Control
GBM patients recevied traditional treatment options (including surgery combined with radiotherapy and chemotherapy)
Treatment
GBM patients recevied surgical combination photodynamic therapy
Interventions
GBM patients recevied surgical combination photodynamic therapy
GBM patients recevied traditional treatment options (including surgery combined with radiotherapy and chemotherapy)
Eligibility Criteria
GBM patients recevied traditional treatment options (including surgery combined with radiotherapy and chemotherapy) or PDT treatment
You may qualify if:
- Pathologically confirmed primary focal GBM; Recurrent GBM(single or satellite lesions); Multiple (multiple germinal centers)GBM.
You may not qualify if:
- Photosensitizer allergy.
- Severe coagulation disorder.
- Patients with severe cardiovascular and cerebrovascular diseases, especially patients in the acute stage.
- Multiple organ failure, end-stage patients. ⑤ Pregnant women: Photofrin is considered a class C pregnancy risk (toxic, non-teratogenic) drug with non-dialysis properties.
- Non-gbm diagnosis: Patients with other types of brain tumors or diseases. 7 Do not agree to informed consent: patients who are unwilling to sign informed consent or do not agree to participate in the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, 310014, China
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Head of neurosurgery department
Study Record Dates
First Submitted
February 10, 2025
First Posted
April 22, 2025
Study Start
June 1, 2025
Primary Completion (Estimated)
June 30, 2027
Study Completion (Estimated)
December 31, 2027
Last Updated
April 22, 2025
Record last verified: 2025-01
Data Sharing
- IPD Sharing
- Will not share